GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Beneish M-Score
中文

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Beneish M-Score

: 0.00 (As of Today)
View and export this data going back to 2021. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Regencell Bioscience Holdings's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Regencell Bioscience Holdings was 0.00. The lowest was 0.00. And the median was 0.00.


Regencell Bioscience Holdings Beneish M-Score Historical Data

The historical data trend for Regencell Bioscience Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
- - - - -

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Beneish M-Score falls into.



Regencell Bioscience Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Regencell Bioscience Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $0.06 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Total Current Assets was $11.62 Mil.
Total Assets was $12.62 Mil.
Property, Plant and Equipment(Net PPE) was $0.89 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.77 Mil.
Selling, General, & Admin. Expense(SGA) was $4.69 Mil.
Total Current Liabilities was $0.61 Mil.
Long-Term Debt & Capital Lease Obligation was $0.03 Mil.
Net Income was $-5.87 Mil.
Gross Profit was $0.21 Mil.
Cash Flow from Operations was $-4.96 Mil.
Total Receivables was $0.03 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Total Current Assets was $16.45 Mil.
Total Assets was $18.02 Mil.
Property, Plant and Equipment(Net PPE) was $1.46 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.60 Mil.
Selling, General, & Admin. Expense(SGA) was $5.11 Mil.
Total Current Liabilities was $0.58 Mil.
Long-Term Debt & Capital Lease Obligation was $0.36 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.057 / 0) / (0.028 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.621 + 0.892) / 12.622) / (1 - (16.445 + 1.46) / 18.019)
=0.008636 / 0.006327
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.604 / (0.604 + 1.46)) / (0.77 / (0.77 + 0.892))
=0.292636 / 0.463297
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4.692 / 0) / (5.106 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.025 + 0.607) / 12.622) / ((0.36 + 0.578) / 18.019)
=0.050071 / 0.052056
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5.871 - 0.211 - -4.963) / 12.622
=-0.088655

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Regencell Bioscience Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus